Skip to Main Content

Try STAT+ TODAY

pharmaceuticals

Most Read

Politics Helen Branswell, Rachel Cohrs and Damian Garde

STAT Plus: 8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel

The Obesity Revolution Isabella Cueto and Theresa Gaffney

‘That scares me’: New childhood obesity guidelines still face a long road to consensus

Pharmalot Ed Silverman

STAT Plus: Sanofi becomes the third leading insulin maker to lower list prices, cutting Lantus price by 78%

Pharmalot Ed Silverman

STAT Plus: Here’s why there aren’t many cheap, generic versions of pricey inhalers

Politics John Wilkerson

STAT Plus: Califf criticizes insurers for doing too little on drug research

Pharmalot Ed Silverman

STAT Plus: U.K. trade group suspends Novo Nordisk for ‘serious breaches’ in promoting obesity drug

Politics Rachel Cohrs

STAT Plus: Medicare explains how it will choose drugs for negotiation

Health Sean Murphy and Matthew Perrone — Associated Press

Texas judge hears arguments in lawsuit to pull long-used abortion pill off the market

All Coverage

Politics Sarah Owermohle

STAT Plus: Senators interrogate health secretary Becerra on Alzheimer’s drug coverage

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: U.K. regulator to streamline clinical trial approvals; NIH won’t seize patents to cut price of cancer drug

advertisement

Health Angus Chen

Study finds same small rise in breast cancer risk in many forms of hormonal birth control

Pharmalot Ed Silverman

STAT Plus: Patient groups balk at former AstraZeneca official negotiating U.K.-India free trade deal

Biotech Allison DeAngelis

STAT Plus: Altimmune’s obesity drug fails to stand out from blockbuster treatments in early data

Health Nicholas Florko

STAT Plus: Arizona plans to dramatically increase hepatitis C testing and treatment in prisons

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Sanofi cuts price on a popular insulin by 78%; Califf criticizes insurers for doing too little on drug research

Pharmalot Ed Silverman

STAT Plus: Democratic lawmakers press pharmacy chains on abortion pill access

Pharma Adam Feuerstein

STAT Plus: French pharma Sanofi buys maker of diabetes treatment for $2.9 billion

Pharma Adam Feuerstein

STAT Plus: Pfizer buys Seagen, maker of targeted cancer drugs, for $43 billion

Health Elaine Chen

Covering new weight loss drugs could strain Medicare, policy experts warn

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: New York officials press pharmacy chains over abortion pill; Sanders pushes bill for $20 insulin cap

First Opinion Alfred Engelberg

STAT Plus: Clearing the patent thicket: A pathway to faster generic drug approvals

Politics Rachel Cohrs

STAT Plus: An unlikely new 340B alliance emerges between PhRMA and community health centers

Politics Rachel Cohrs

STAT Plus: Pfizer CEO Albert Bourla maxed out campaign contributions to Dr. Oz ahead of midterm elections

Health Tech Ben Brody

STAT Plus: ‘Truth is losing the battle’: FDA commissioner on grappling with a wave of health misinformation

Pharmalot Ed Silverman

STAT Plus: Controversial drug for premature birth is withdrawn by manufacturer after battle with FDA

Politics Andrew Joseph

STAT Plus: Q&A: Califf on obesity drugs, advisory panels, and how threats hurt recruitment at FDA

Health Rick Berke

A letter from the executive editor: The Obesity Revolution

Pharma Matthew Herper

STAT Plus: After its drug was shown to prevent heart attacks, what’s next for Esperion?

First Opinion John Stanford

Congress must fix the IRA’s small molecule penalty

Politics John Wilkerson

STAT Plus: By cutting insulin prices, Eli Lilly avoids paying big Medicaid rebates

The Obesity Revolution Elaine Chen and Matthew Herper

STAT Plus: New weight loss drugs are changing the narrative on obesity, with a push from pharma